Express Scripts, one of the large pharmacy benefit managers, has released its 2015 Drug Trend Report. Today we will concentrate on the headline numbers. (Express Scripts Report) Overall drug spending for Express Scripts’ clients increased 5.2% in 2015. Member’s share of that spending through copays, deductibles or coinsurance declined 3.2%. For its customers who used what Express Scripts defines as a “tightly managed” drug benefit program, spending growth was only 3.3%, and 30% of its customers had flat or negative drug spending trends. The total per member per year drug spending was $1061, with $708 of that being traditional medications and $353 being specialty drugs. The traditional category had utilization growth of 1.9% and a price decrease of 2.1% for a total trend of negative one-tenth of a percent. The specialty category had a 6.8% utilization increase and an 11% price rise, for total trend of 17.7%. The company says that manufacturer consolidation, price increases on drugs with imminent patent expirations and very large price increases on older drugs with no competition contributed to ongoing unit price rises that were very high in some cases. According to the company, one-third of branded drugs had price increases in 2015 of over 20% and the average price increase on a branded medication in 2015 was 16.2%, and was 98.2% since 2011. Specialty drugs, while used by only 1-2% of the population, accounted for over one-third of all drug spending and Express Scripts expects that to rise to 50% by 2018. In the specialty category, spending growth is highest in categories like cystic fibrosis, hemophilia, sleep disorders, oncology and inflammatory conditions, which includes rheumatoid arthritis. The traditional category saw its largest spending rises in heartburn, skin conditions and diabetes, while blood pressure, high cholesterol and compounded drugs actually saw decreases. Looking ahead, the PBM expects drug trend to be 6.8% in 2016, 7.3% in 2017 and 8.4% in 2018, all heavily influenced by specialty drug spending that the company anticipates will increase by 17% a year in this time period.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
It may be investors that need the redesign. They just keep pouring money into this digital health crap despite all the losses. Redesign Health claims that it makes money by...
September 16, 2022
In truth, this seems like more money down a rathole. Google’s parent and other investors are putting a billion dollars into Google’s health arm, Verily. Apparently want to compete with...
September 12, 2022
It is like investors have learned nothing from the past two years. Even supposedly smart investors like Morgan Health, which is making a $20 million contribution to LetsGetChecked, which supposedly...
September 12, 2022
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace